Insights from BCC Research

Laurie L. Sullivan

Recent Posts

Computational Approaches Opening New Frontiers in Drug Discovery

Posted by Laurie L. Sullivan on Feb 26, 2018 11:00:00 AM

Drug Discovery.jpegGlobally, the rise in research expenditures, deterioration in human health conditions and the need for novel and effective therapies have boosted the demand for drug discovery tools. In just the last few years, the drug discovery and development industry has undergone a major transition, with increased calls for efficient, user-friendly and affordable products. A new study by BCC Research examines all aspects of the drug discovery process, which consumes a major portion of drug development costs. Therefore, it is imperative for companies to use technologies that offer a high probability that their future drug product will be commercially successful.

Read More

Topics: Life Sciences, Biotechnology

Among Other Apps, Smart Pills Could Help Staunch the Opioid Epidemic

Posted by Laurie L. Sullivan on Feb 7, 2018 11:30:00 AM

Pill_Bottle.jpgThe opioid epidemic continues as one of America’s greatest public health crises as healthcare officials, public officials and countless Americans struggle to prevent opioid abuse, addiction and death. In a blog from 2017, Laurie Sullivan explores how one solution, known as The Smart Pill Drug Delivery Device, could be used to curb the crisis. Another possible solution? Prescribing more non-opioid painkillers. Click here to be notified when the BCC Research report “Non-opioid Pain Treatment: Global Markets to 2022” publishes later this month.

Smart pills are increasingly influencing our health. They are noninvasive and have redefined diagnosis, disease monitoring, and treatment adherence. By 2021, US sales of smart pills may double, reaching $1.2 billion. The global market for smart pills is poised to exceed a 20% compound annual growth rate (CAGR) during the next five years, according to BCC Research’s recent study, Smart Pills: Applications and Global Markets. High-growth application areas include capsule endoscopy, patient monitoring, and delivery of therapeutic agents. The adoption of advanced ingestible medical sensor technologies is a key growth driver.

Read More

Topics: Life Sciences, Pharmaceuticals

Cloud Computing Is Capturing Healthcare

Posted by Laurie L. Sullivan on Feb 1, 2018 12:45:00 PM

Cloud_Computing.pngInitially approached with caution by healthcare organizations, cloud computing is becoming more widely adopted in this arena. As cost savings outweighed potential data protection concerns, cloud adoption in healthcare increased during 2017. Healthcare information technology (IT) systems are expensive to implement, update and maintain. Cloud economics changes that by shifting from individual budgets to cost-sharing models enabled by private, multitenant and in some cases, public clouds. These trends are shifting in favor of increased IT spending on cloud hardware, software and networks.

Read More

Topics: Life Sciences, Healthcare

Market for Enzyme Inhibitors Faces Generic Competition, Payer Pushback

Posted by Laurie L. Sullivan on Jan 16, 2018 10:00:00 AM

Enzyme_Inhibitor copy.jpgThe development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.

Read More

Topics: Life Sciences, Biotechnology